Meeting Report Volume 10, Issue 11 pp 3079—3088
Aging and drug discovery
- 1 Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark
- 2 Pharmaceutical Artificial Intelligence Department, Insilico Medicine, Inc., Baltimore, MD 20850, USA
- 3 Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 4 Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- 5 Buck Institute for Research on Aging, Novato, CA 94945, USA
- 6 Lawrence Berkeley National Laboratory, Life Sciences Division, Berkeley, CA 94720, USA
- 7 Institute of Translational Medicine, Department of Health Sciences and Technology, Swiss Federal Institute for Technology (ETH) Zürich, Switzerland
- 8 Youth Laboratories, Moscow, Russia
- 9 Division of Genetics, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA
- 10 Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia
- 11 Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada
- 12 Pathway Rx Ltd, Lethbridge, Alberta, Canada
- 13 Department of Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA
- 14 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
- 15 Pancreatic Islet Development and Regeneration Unit/Laboratory of Aging Biology, Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad de Sevilla-CSIC-Universidad Pablo de Olavide, Seville, Spain
- 16 Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 17 Translational Neurobiology Group, Center of Molecular Neurology, VIB, Antwerp, Belgium
- 18 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
- 19 Institute of Biology of Komi Science Center of Ural Branch of RAS, Syktyvkar, Russia
- 20 Moscow Institute of Physics and Technology, Dolgoprudny, Russia
- 21 Division of Epidemiology and Biostatistics University of Illinois at Chicago School of Public Health, Chicago, IL 60612, USA
- 22 Juvenescence Limited, Douglas, Isle of Man, UK
Received: October 8, 2018 Accepted: November 4, 2018 Published: November 13, 2018
https://doi.org/10.18632/aging.101646How to Cite
Copyright: Bakula et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Multiple interventions in the aging process have been discovered to extend the healthspan of model organisms. Both industry and academia are therefore exploring possible transformative molecules that target aging and age-associated diseases. In this overview, we summarize the presented talks and discussion points of the 5th Annual Aging and Drug Discovery Forum 2018 in Basel, Switzerland. Here academia and industry came together, to discuss the latest progress and issues in aging research. The meeting covered talks about the mechanistic cause of aging, how longevity signatures may be highly conserved, emerging biomarkers of aging, possible interventions in the aging process and the use of artificial intelligence for aging research and drug discovery. Importantly, a consensus is emerging both in industry and academia, that molecules able to intervene in the aging process may contain the potential to transform both societies and healthcare.